scholarly journals Intra- and Postoperative Very Low Dose Intravenous Ketamine Infusion Does Not Increase Pain Relief after Major Spine Surgery in Patients with Preoperative Narcotic Analgesic Intake

Pain Medicine ◽  
2011 ◽  
Vol 12 (8) ◽  
pp. 1276-1283 ◽  
Author(s):  
Kathirvel Subramaniam ◽  
Vimal Akhouri ◽  
Paul A. Glazer ◽  
Jacob Rachlin ◽  
Lisa Kunze ◽  
...  
2021 ◽  
Author(s):  
Shirin Ghanavatian ◽  
Dominika Lipowska James ◽  
Joshua Simon Sadolf

2016 ◽  
Vol 8 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Scott J. Sherman ◽  
Miguel Estevez ◽  
Ari B. Magill ◽  
Torsten Falk

Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a ‘chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients.


2020 ◽  
Vol 4 ◽  
pp. 247054702098167
Author(s):  
Alisher R. Dadabayev ◽  
Sonalee A. Joshi ◽  
Mariam H. Reda ◽  
Tamar Lake ◽  
Mark S. Hausman ◽  
...  

Objective To date, treatment options (i.e. psychotherapy, antidepressant medications) for patients with posttraumatic stress disorder (PTSD), are relatively few, and considering their limited efficacy, novel therapies have gained interest among researchers and treatment providers alike. Among patients with chronic pain (CP) about one third experience comorbid PTSD, which further complicates their already challenging pharmacological regimens. Low dose ketamine infusion has shown promise in PTSD, and in treatment of CP, however they have not been studied in comorbid population and under rigorous control conditions. Methods We compared the effects of a single dose of either ketamine (0.5 mg/kg) or ketorolac (15 mg) over a 40-minute of IV infusion in CP patients with and without PTSD, in double blind, randomized study. Measures were collected before, during, one day and seven days after the infusion. A planned sample size of 40 patients randomly assigned to treatment order was estimated to provide 80% power to detect a hypothesized treatment difference after the infusion. Main Outcome and Measures: The primary outcome measures were change in PTSD symptom severity assessed with the Impact of Event Scale–Revised (IES-R) and Visual Analogue Scale (VAS) for pain administered by a study clinician 24 hours post infusion. Secondary outcome measures included Impact of Event Scale–Revised (IES-R), VAS and Brief Pain Inventory (Short Form) for pain 1 week after the infusion. Results Both treatments offered comparable improvement of PTSD and CP symptoms that persisted for 7 days after the infusion. Patients with comorbid PTSD and CP experienced less dissociative side effects compared to the CP group. Surprisingly, ketorolac infusion resulted in dissociative symptoms in CP patients only. Conclusions This first prospective study comparing effects of subanesthetic ketamine versus ketorolac infusions for comorbid PTSD and CP, suggests that both ketamine and ketorolac might offer meaningful and durable response for both PTSD and CP symptoms.


Sign in / Sign up

Export Citation Format

Share Document